Description: Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Home Page: www.hrs.com.cn
38 Huanghe Rd Eco & Tech Dev Park
Lianyungang,
222000
China
Phone:
86 518 8122 0983
Officers
Name | Title |
---|---|
Mr. Jianjun Liu | Financial Director |
Ms. Su Mei Jiang | Exec. Deputy GM & Director |
Mr. Jie Ping Sun | Deputy GM & Director |
Mr. Hong Bin Dai | Deputy GM & Director |
Dr. Lian Shan Zhang Ph.D. | Deputy GM & Director |
Mr. Kai Hong Yuan | Deputy Gen. Mang. |
Mr. Ya Ping Shen | Deputy Gen. Mang. |
Mr. Xu Gen Sun | Deputy Gen. Mang. |
Mr. Wei Kang Tao | Deputy Gen. Mang. |
Mr. Cheng Liao | Deputy Gen. Mang. |
Exchange: SHG
Country: CN
Currency: Renminbi (¥)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 52.356 |
---|---|
Trailing PE: | 71.4 |
Price-to-Book MRQ: | 6.7378 |
Price-to-Sales TTM: | 11.1836 |
IPO Date: | 2000-09-07 |
Fiscal Year End: | December |
Full Time Employees: | 24491 |